News Channels

07 Jun 2017 AFFiRiS announces top line results of first-in-human clinical study using Affitope® PD03A, confirming immunogenicity and safety profile in Parkinson's disease patients
07 Jun 2017 NanoViricides Reports Excellent Inhibitory Effects of Its Topical Shingles Treatment Candidates Against VZV in Multiple Cell Culture Studies
07 Jun 2017 Jazz Pharmaceuticals Presents Data for the Phase 3 TONES 2 Study of JZP-110 in Patients with Excessive Sleepiness Associated with Narcolepsy
07 Jun 2017 Oragenics Presents Development of Novel Lantibiotic Against Clostridium difficile at the ICAAC Conference
07 Jun 2017 CVT-301 Phase 3 Data Showed Significantly Improved Motor Function During OFF Periods in Parkinson’s Disease
06 Jun 2017 CRISPR Therapeutics and MaSTherCell SA sign service agreement for the development and manufacturing of allogeneic cell therapies
06 Jun 2017 AbCellera Announces an Antibody Discovery Program in Influenza Vaccine Research
06 Jun 2017 Exploratory Analysis of the Phase I/II CHRYSALIS Study of gilteritinib Demonstrates First Molecular Response to FLT3 Inhibitor in Acute Myeloid Leukemia
06 Jun 2017 Updated Data from Phase 1 Trial of Oral IDHIFA® (enasidenib) Demonstrate Complete Responses and Duration of Response in Patients with Relapsed or Refractory AML and an IDH2 Mutation
06 Jun 2017 Refixia® (nonacog beta pegol; N9-GP) approved
06 Jun 2017 Affimed Presents Data on First-in-Class BCMA-Targeting Immune Cell Engager AFM26 at ASCO Annual Meeting 2017
06 Jun 2017 Intellia Therapeutics and San Raffaele University and Research Hospital to Combine CRISPR/Cas9 Genome Editing with Enhanced Cell Therapies to Fight Cancer
06 Jun 2017 Eiger Completes Enrollment in Phase 2 Multiple-Ascending Dose Study of Exendin 9-39 in Post-Bariatric Hypoglycemia Patients
06 Jun 2017 Aldeyra Therapeutics Announces First Patient Enrolled in Dry Eye Disease Phase 2a Clinical Trial
06 Jun 2017 Viking Therapeutics Announces Promising Top Line Results from In Vivo Study of VK2809 in Non-Alcoholic Steatohepatitis (NASH)
06 Jun 2017 FDA Approves Two-Month ARISTADA® for Treatment of Schizophrenia
06 Jun 2017 Eleven Biotherapeutics to Collaborate with AstraZeneca and the National Cancer Institute on Development of ViciniumTM in Combination with Durvalumab for the Treatment of Non-Muscle Invasive Bladder Cancer
06 Jun 2017 NIH and Themis Bioscience announce the initiation of a clinical trial of a Chikungunya vaccine
06 Jun 2017 TRACON Pharmaceuticals Presents Positive Clinical Data from TRC105 and TRC102 Studies at American Society of Clinical Oncology (ASCO) 2017 Annual Meeting
06 Jun 2017 Celldex Therapeutics Presents Phase 1 Study of Varlilumab and Opdivo® at 2017 ASCO Annual Meeting

La Merie Biologics

FREE Weekly News Bulletin

2016 Sales ofAntibodies & Proteins

New Product Alert

For La Merie Publishing

Top